Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

BMY remains a speculative dividend play here, with it remaining to be seen when the correction may end and if the floor may hold at $48s. While Revlimid's top-line erosion appears to be decelerating, the management faces another LOE issue for Eliquis by 2026. It is unsurprising then, that BMY has opted for numerous partnerships and acquisitions to bolster its pipeline, though with an 8% clinical approval rate, nothing is certain at this point.

Bristol-Myers Squibb: Too Many Headwinds To Ignore, Despite The Stellar

Karuna Therapeutics Inc

NEW YORK , Dec. 22, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Karuna Therapeutics, Inc. (NASDAQ: KRTX) and its board of directors concerning the proposed acquisition of the company by Bristol Myers Squibb (NYSE: BMY). Stockholders will receive $330.00 for each share of Karuna Therapeutics stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Karuna Therapeutics, Inc.

Shares of biopharmaceutical company Karuna Therapeutics skyrocketed more than 47% Friday morning after giant Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) announced a deal to acquire the company in a $14 billion cash deal.  The agreement valued Karuna at $330 per share.

Bristol Myers Squibb buys neurological drug developer Karuna Therapeutics in $14B deal

Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.

Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B

NIKE

U.S. equities headed into the long holiday weekend with gains at midday, amid a broad-based rally fueled by enthusiasm over the possibility of several Fed interest rate cuts next year. The Dow, S&P 500, and Nasdaq were all up.

Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook

Karuna Therapeutics (KRTX) shares skyrocketed over 46% after Bristol Myers Squibb (BMY) said it would buy the biopharmaceutical firm for $14 billion to expand its neuroscience portfolio.

Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna Deal

Dec 22 (Reuters) - Bristol Myers Squibb (BMY.N) on Friday agreed to buy Karuna Therapeutics (KRTX.O) for $14 billion, gaining a promising new type of antipsychotic medicine to help power growth as patents on its older therapies expire later this decade.

Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 bln

Bristol-Myers Squibb Co (NYSE:BMY) stock is on the rise today, up 2.8% at $52.71 at last glance, after news that the biopharmaceutical company is acquiring Karuna (KRTX) for $14 billion.

Bristol-Myers Jumps on Billion-Dollar Buzz

Amgen

AstraZeneca

BioMarin Pharmaceutical

Blueprint Medicines

Pfizer

Roche Holding AG

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

Biotech stocks set for a rebound in 2024, analysts say

Bristol Myers Squibb said it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash.

Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal

Carnival

Micron Technology

Paramount Global

Warner Bros Discovery Inc

Wells Fargo

Before U.S. markets opened on Friday, the Bureau of Economic Analysis released its personal income and spending report for November.

A Major Acquisition and Other News Ahead of the Holiday Weekend

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Karuna Therapeutics, Inc., and (Nasdaq: KRTX) Bristol Myers Squibb (NYSE: BMY) announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.

PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion

Bristol Myers Squibb announced its $14 billion acquisition of Karuna Therapeutics on Friday, sending KRTX stock into the stratosphere.

Karuna Stock Soars On Bristol Myers' $14 Billion Takeover

Karuna's crown jewel, an experimental drug called KarXT, is the product of such new insights. The drug could surpass $6 billion in yearly sales if it is approved for the various uses.

Bristol Myers to buy Karuna Therapeutics for $14B

PRINCETON, N.J. & BOSTON--(BUSINESS WIRE)---- $KRTX--Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors. Ka.

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

Karuna has an experimental schizophrenia drug called KarXT up for U.S. government approval.

Bristol Myers to Buys Karuna Therapeutics in $14 Billion Pharma Deal: Report

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Present at J.P. Morgan's 42nd Annual Healthcare Conference.

Bristol Myers Squibb to Present at J.P. Morgan's 42nd Annual Healthcare Conference

Shares of Karuna Therapeutics Inc. KRTX, +1.80% rocketed 33.8% into record territory in premarket trading Friday, after The Wall Street Journal reported that Bristol Myers Squibb Co. BMY, +0.59% has reached an agreement to buy the drug developer in a deal valued at $14 billion. Bristol Myers' stock slumped 2.7% ahead of the open.

Karuna Therapeutics' stock rockets into record territory after report Bristol Myers' $14 billion buyout agreement

Burlington Stores

C.H. Robinson Worldwide

Goodyear Tire & Rubber

Kohl's

Microsoft

Newell Brands

Procter & Gamble

Ralph Lauren

Tesla

Westamerica Bancorp

Stock newsletter writers don't pop up much on CNBC, but that doesn't mean you should ignore these unsung market heroes. Many are great analysts with solid long-term records.

These unsung stock market heroes offer 9 favorite picks for 2024

Allogene Therapeutics Inc

BeiGene

Eli Lilly

Tango Therapeutics

With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.

3 Cancer-Focused Biotechs That Appear Promising Bets for 2024

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference.

Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference

Bio-Rad Laboratories

Cigna

Humana

Incyte

Moderna

After an abysmal year for healthcare stocks, Wall Street is upbeat on Cigna, Humana, Bristol Myers, and three others.

6 Stock Picks in Healthcare for 2024

Albemarle

First Solar

This past year was great for investors. Granted, there were some bumps and bruises along the way, with inflation, rising interest rates, a regional banking crisis and troubling geopolitical issues.

3 Potential Turnaround Stocks to Buy for Big Rewards in 2024

Bristol Meyers Squibb's stock is down nearly 15% over the past 3 years and currently trades at a price to earnings of less than 15x, indicating it is undervalued. BMY recently announced a deal worth $8.4 billion and another deal to acquire a biotech company, signaling their commitment to growth. BMY's dividend is well-covered, with a safe payout ratio of roughly 41%, and the company has increased its dividend by 5.3%. They also have a flexible share repurchase program.

Bristol Myers Squibb: This Dividend Contender Is A Steal Right Now

Merck

Large-cap pharma stocks often pay robust dividend yields. Bristol Myers Squibb and Merck are two of the most generous dividend-payers within the category.

News for Bristol-Myers Stock (BMY)